Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study

[1]  H. Kennecke,et al.  Impact of Travel Distance and Urban‐Rural Status on the Multidisciplinary Management of Rectal Cancer , 2017, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[2]  I. Durand-zaleski,et al.  Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study) , 2017, PloS one.

[3]  Nicholas Moore,et al.  The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology , 2017, Pharmacoepidemiology and drug safety.

[4]  James C. Robinson,et al.  Value-based payment for oncology services in the United States and France , 2017 .

[5]  B. Jönsson,et al.  The cost and burden of cancer in the European Union 1995-2014. , 2016, European journal of cancer.

[6]  F. Menegaux,et al.  Estimation of breast, prostate, and colorectal cancer incidence using a French administrative database (general sample of health insurance beneficiaries). , 2016, Revue d'epidemiologie et de sante publique.

[7]  J. Bonastre,et al.  The 5000% case: a glimpse into the financial issue of lung cancer treatment , 2016, European Respiratory Journal.

[8]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[9]  J. Donovan,et al.  A systematic review of geographical variation in access to chemotherapy , 2015, BMC Cancer.

[10]  G. Milano.  Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations. , 2015, Chinese clinical oncology.

[11]  J. Blay,et al.  Lung cancer risks, beliefs and healthcare access among the underprivileged , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[12]  G. de Pouvourville,et al.  Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals? , 2014, Health policy.

[13]  F. Burge,et al.  Inequity in access to guideline-recommended colorectal cancer treatment in Nova Scotia, Canada. , 2012, Healthcare policy = Politiques de sante.

[14]  S. Ahmed,et al.  Disparity in cancer care: a Canadian perspective. , 2012, Current oncology.

[15]  P. Stephens,et al.  The Cancer Drug Fund 1 year on--success or failure? , 2012, The Lancet. Oncology.

[16]  M. Peake,et al.  Exploring variations in lung cancer care across the UK--the 'story so far' for the National Lung Cancer Audit. , 2012, Clinical medicine.

[17]  A. Girgis,et al.  Travelling all over the countryside: travel-related burden and financial difficulties reported by cancer patients in New South Wales and Victoria. , 2011, The Australian journal of rural health.

[18]  P. Tagliaferri,et al.  Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM) , 2010, Tumori.

[19]  D. Forman,et al.  Social and geographical factors affecting access to treatment of lung cancer , 2009, British Journal of Cancer.

[20]  Grégoire Rey,et al.  Ecological association between a deprivation index and mortality in France over the period 1997 – 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death , 2009, BMC public health.

[21]  S. Verma,et al.  Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada , 2007, Current oncology.

[22]  H. Møller,et al.  Variation in the use of chemotherapy in lung cancer , 2007, British Journal of Cancer.

[23]  P. Rosenbaum,et al.  Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography. , 2006, Health services research.

[24]  D. Menon,et al.  Access to drugs for cancer: Does where you live matter? , 2005, Canadian journal of public health = Revue canadienne de sante publique.

[25]  D. Menon,et al.  Access to Drugs for Cancer , 2005 .

[26]  A. Moore.  Cancer care. Still no sign of winning tickets in cancer care lottery. , 2005, The Health service journal.

[27]  J. Mandelblatt,et al.  Equitable access to cancer services , 1999, Cancer.

[28]  F. Jones,et al.  International Classification of Diseases , 1978 .

[29]  David Hughes.  L'accès aux médicaments anticancéreux onéreux au Canada : une comparaison entre le Québec, l'Ontario et la Colombie-Britannique , 2012 .